Presentations highlight momentum of Pfizer’s
portfolio of infectious disease prevention and treatment
options
Pfizer Inc. (NYSE: PFE) will present data across its infectious
disease portfolio at the upcoming IDWeek 2024 congress, held in Los
Angeles from October 16-19, 2024. Data in 49 abstracts from
company- and collaborator-led studies, will highlight the advances
Pfizer is making in helping prevent and treat infectious
diseases.
“Pfizer is at the forefront of vaccine and therapeutic
development in respiratory and infectious diseases,” said Annaliesa
Anderson, Ph.D., Senior Vice President and Head, Vaccine Research
and Development, Pfizer. “IDWeek 2024 provides a crucial platform
to showcase our innovative advancements and engage with the
scientific community, as we work to effectively tackle the ongoing
challenge posed by infectious diseases.”
"As we approach another respiratory virus season, the importance
of preventive vaccines and treatments to help keep us healthy is
more apparent than ever,” said Luis Jodar, Ph.D., Chief Medical
Affairs Officer, Vaccines/Antivirals, Pfizer. “We’re excited to
present new, meaningful data that we hope will help further inform
healthcare providers.”
Pfizer will present research from its robust infectious disease
portfolio, covering RSV, COVID-19, pneumococcal disease, Lyme
disease, meningococcal disease, and serious bacterial and fungal
infections. Details for Pfizer-sponsored, investigator-sponsored
and collaborative research oral and poster presentations are
below:
Title/Abstract Number
Presenting Name/Type
Date/Time (PDT)
Location
ORAL & LATE-BREAKING
PRESENTATIONS
580 - Pharmacokinetics (PK) and Safety of
Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic
Pediatric Patients Ages 6 Years and Older with COVID-19 Who Are at
Increased Risk of Progression to Severe Disease (EPIC-Peds)
Jacqueline Gerhart, PhD
Oct 19 2:45 – 2:57 PM US PT
403 A
88 - Efficacy of Nirmatrelvir/Ritonavir in
High-Risk Trial Participants With Prior SARS-CoV-2 Infection or
Vaccination: A Pooled Analysis
John M. McLaughlin, PhD
Oct 17 10:42 – 10:54 AM US PT
411
165 - Real-world Abrysvo vaccine
effectiveness (VE) against Respiratory Syncytial Virus
(RSV)-related severe acute respiratory infection (ARI)
hospitalizations and emergency department (ED) visits—Kaiser
Permanente of Southern California (KPSC), November 2023-April
2024
Sara Tartof, PhD, MPH, (KPSC)*
Oct 17 1:45 – 3:00 PM US PT
403A
571 – Safety and Immunogenicity of
Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent
RSVpreF Respiratory Syncytial Virus Vaccine With and Without
Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Rahsan Erdem, MD
Oct 19 1:45 – 2:03 PM US PT
408 A
POSTER PRESENTATIONS
COVID-19
P - 1194 - Comparison of COVID-19
Inpatient Burden in Hospitalized Children Age < 5years, by
SARS-CoV-2 Variant
Kathleen M. Andersen, PhD MSc
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1906 - Early COVID-19 and Severity of
Subsequent Omicron Infection in Ontario, Canada
Caroline Kassee, MPH
(Sinai Health)*
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 1977 - Six-Month Trajectory of
Symptoms of COVID-19 Fatigue by Age and BNT162b2 COVID-19
Vaccination Status: A Prospective Study Among Symptomatic US Adults
Testing Positive for SARS-CoV-2 at a National Retail Pharmacy
Manuela Di Fusco, PhD
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2047 - Public Health Impact and
Economic Value of an Additional Dose of Pfizer-BioNTech
XBB.1.5-adapted COVID-19 Vaccine for Older Adults in the United
States
Alon Yehoshua, PharmD, MS
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2048 - COVID-19 XBB.1.5 vaccine uptake
based on state vaccine registries compared to national survey
data
Angela Cook, MS
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2054 - Effectiveness of a Single
COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with
SARS-CoV-2: A Systematic Review
Hannah R. Volkman, PhD, MPH
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2060 - Effectiveness of BNT162b2
COVID-19 Vaccination Against Long COVID Among Older Adults: A
Nationwide Study
Manuela Di Fusco, PhD
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2062 - COVID-19 XBB.1.5-adapted
vaccine uptake in immunocompromised individuals using tokenized
state vaccine registries
Matthew A. Brouillette, MPH
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
P - 2017 - Patient Reported Outcomes of
Nirmatrelvir/Ritonavir Treatment for High-risk, Nonhospitalized
Adults with Symptomatic COVID-19
Ashley S. Cha-Silva, PharmD, MS
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
Lyme Disease
P - 599 - 6-Valent, OspA-Based VLA15 Lyme
Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy
Pediatric and Adult Study Population: A Phase 2 Study Update
James H. Stark, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 1287 - Incidence of Symptomatic Lyme
Borreliosis in Nine European Countries, 2018−2022
Frederick Angulo, DVM PhD
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1291 - Racial disparities in Lyme
disease among beneficiaries of US Medicaid and Medicare
L. Hannah Gould, PhD, MS, MBA
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1293 - Healthcare Costs Associated
with Lyme Disease in a U.S. Insured Population
Holly Yu, MSPH
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
Meningococcal Disease
P - 1299 - Epidemiology of Invasive
Meningococcal Disease in the United States: Review of Recent Data
and Identified Risk Factors
Jessica Presa, MD
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1304 - Public Health Impact of changes
to Meningococcal vaccination platform in the United States
Katharina Schley, Dr. rer pol.
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
Pneumococcal disease
P - 8 - Assessment of 13-valent
pneumococcal conjugate vaccine effectiveness among people living
with HIV in the United States
Amanda C. Miles, MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 628 - Real-world impact of
pneumococcal conjugate vaccines on vaccine serotypes and
cross-reacting non-vaccine serotypes
Kevin Apodaca, MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 629 - The health and economic impact
of the PCV15 and PCV20 priming series during the first year of life
in the US
Mark Rozenbaum, PhD, M.B.A
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
Respiratory Syncytial Virus
(RSV)
P - 673 - Respiratory Syncytial Virus
(RSV) Hospitalizations During Off-Season Months Among Infants in
US
Amy W. Law, PharmD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 674 - The Economic Burden of Infant
RSV Among US Caregivers
Amy W. Law, PharmD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 40 - Impact of case and control
selection on influenza vaccine effectiveness (VE) among adults aged
40 years and older hospitalized with acute respiratory illness
(ARI) during 2022-2023 using a test negative design (TND):
secondary analysis of the North America Multi-Specimen Study
Negar Aliabadi, MD, MS
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 1204 - Hospitalizations Associated
with Respiratory Syncytial Virus (RSV) Illness Among Children and
Adolescents in Ontario, Canada
Sazini Nzula, PhD
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1205 - Impact of the COVID-19 Pandemic
on Hospitalizations Associated with Respiratory Syncytial Virus
(RSV) Illness Among Children and Adolescents in Ontario, Canada
Sazini Nzula, PhD
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 677 - Estimation of Respiratory
Syncytial Virus-Attributable Hospitalizations Among Older Adults in
Japan between 2015 and 2018: An Administrative Health Claims
Database Analysis
Asuka Yoshida, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 680 - Estimated Respiratory Syncytial
Virus (RSV)-Related Hospitalizations and Deaths Among Adults in
Norway between 2010–2019
Caihua Liang, MD, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 682 - The Risk of Cardiorespiratory
Events for Up to 180 days Following Respiratory Syncytial Virus
(RSV) Infection Hospitalization: A Self-Controlled Case Series
Analysis
Caihua Liang, MD, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P – 683 – Estimation of RSV-Attributable
Cardiovascular and Respiratory Hospitalizations in Adults in
Germany, Between 2015-2019
Caroline Beese
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 604 - Preliminary real-world Abrysvo
vaccine effectiveness (VE) against Respiratory Syncytial Virus
(RSV)-related lower respiratory tract disease (LRTD)
hospitalizations and emergency department (ED) visits—Kaiser
Permanente of Southern California (KPSC) November 2023-April
2024
Negar Aliabadi, MD, MS
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 53 - Trends in Co-administration of
Adult Vaccinations in the US Retail Pharmacy Setting
Reiko Sato, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 603 - Potential Public Health Impact
of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of RSV
Among Older Adults in the United States
Reiko Sato, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 600 - Efficacy Of a Bivalent RSVpreF
Vaccine in Older Adults Across a Second RSV Season
John Woodside, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 596 - Immunobridging Demonstrating
Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV)
Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High
Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT
Study Results
Elliot N. DeHaan, MD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 681 - Estimated Incidence of
Respiratory Syncytial Virus (RSV)-Related Hospitalizations for
Acute Respiratory Infections (ARIs), including Community Acquired
Pneumonia (CAP), in Adults in Germany
Caihua Liang, MD, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 605 - Bivalent RSV Prefusion F-Based
Subunit Vaccine Generates High and Durable Neutralizing Titers
Across an Entire RSV Season Among Older Adults
Tarek Mikati, MD, MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 595 - Public Health Impact of RSVpreF
Vaccination on Older Adult Disease Outcomes
Daniel Eiras, MD, MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 21 - Comparison of Three RSV Vaccine
Lower Respiratory Tract Disease Primary Endpoint Definitions for
Adult Vaccine
Sarah E. Williams, MD. MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 2357 - Respiratory Syncytial Virus
(RSV) Disease Burden Among Adults in Primary Care Settings in
High-Income Countries: A Systematic Review and Modelling Study
You Li; multiple Pfizer co-authors
Oct 19 12:15 – 1:30 PM US PT
Hall J & K
Aztreonam-Avibactam
P - 105 - Aztreonam-Avibactam Compared
with Adjunctive Colistin Combined with Meropenem for the Treatment
of Serious Gram-Negative Bacterial Infections: Subgroup Analysis of
the Phase 3 REVISIT Study
Heidi Leister-Tebbe, BSN
Oct 17 12:15-1:30 PM US PT
Hall J & K
P - 1080 Aztreonam-Avibactam Activity
Against Gram-negative Bacteria Isolated From Patients with
Pneumonia from Europe, Asia, and Latin America (2021–2023)
Helio S. Sader, MD, PhD, FIDSA
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
P - 1256 - Pharmacokinetic/Pharmacodynamic
(PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing
Regimens
Susan Raber*, PharmD, MPH
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 1508 - In Vitro Activity of
Aztreonam-Avibactam Against Enterobacterales Isolates Producing
Multiple β-lactamases Collected Globally as a Part of the ATLAS
Global Surveillance Program From 2018-2022
Mark Estabrook*, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P - 1509 - In Vitro Activity of
Aztreonam-Avibactam Against Enterobacterales Isolated From
Pediatric and Adult Patients Collected During the ATLAS Global
Surveillance Program, 2018-2022
Mark Estabrook*, PhD
Oct 18 12:15 – 1:30 PM US PT
Hall J & K
Isavuconazole
P - 1168 - Activity of Isavuconazole and
Comparator Agents Against Pediatric Fungal Isolates Collected from
2017–2023 in a Global Surveillance Program
Marisa Winkler, MD, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
Ceftazidime-Avibactam
P- 1506 - In Vitro Activity of
Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas
aeruginosa Collected from Patients with Presumed Hospital- and
Community-Acquired Respiratory Tract Infections as a Part of the
ATLAS Global Surveillance Program 2018-2022
Mark Estabrook, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
P- 1507 - In Vitro Activity of
Ceftazidime-Avibactam Against Enterobacterales Isolates Producing
Multiple β-lactamases Collected Globally as a Part of the ATLAS
Global Surveillance Program from 2018-2022
Mark Estabrook, PhD
Oct 17 12:15 – 1:30 PM US PT
Hall J & K
* =multiple Pfizer co-authors
Prescribing Information for Pfizer Medicines
Please see full Prescribing Information for ABRYSVO®
(Respiratory Syncytial Virus Vaccine) or visit
https://abrysvoadult.pfizerpro.com/ and
https://abrysvomaternal.pfizerpro.com/.
Please see full Prescribing Information for COMIRNATY® (COVID-19
Vaccine, mRNA) or visit https://comirnatyhcp.com.
Please see full Prescribing Information for CRESEMBA®
(Isavuconazonium Sulfate) or visit www.cresemba.com.
Please see full Prescribing Information for PAXLOVIDTM
(Nirmatrelvir and Ritonavir) or visit
https://paxlovid.pfizerpro.com.
Please see full Prescribing Information for PREVNAR 20TM
(Pneumococcal 20-valent Conjugate Vaccine) or visit
https://prevnar20.pfizerpro.com/.
Please see full Prescribing Information for PREVNAR 13®
(Pneumococcal 13-valent Conjugate Vaccine).
Please see full Prescribing Information for ZAFICEFTA®
(Ceftazidime-Avibactam).
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
175 years, we have worked to make a difference for all who rely on
us. We routinely post information that may be important to
investors on our website at www.Pfizer.com. In addition, to learn
more, please visit us on www.Pfizer.com and follow us on X at
@Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this
release is as of October 8, 2024. Pfizer assumes no obligation to
update forward-looking statements contained in this release as the
result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s
infectious disease pipeline, in-line products and product
candidates, including their potential benefits, that involves
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. Risk and uncertainties include, among other things,
uncertainties regarding the commercial success of Pfizer’s
infectious disease products and product candidates; the
uncertainties inherent in research and development, including the
ability to meet anticipated clinical endpoints, commencement and/or
completion dates for our clinical trials, regulatory submission
dates, regulatory approval dates and/or launch dates, as well as
the possibility of unfavorable new clinical data and further
analyses of existing clinical data; risks associated with interim
and preliminary data; the risk that clinical trial data are subject
to differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from our clinical studies; whether and
when any drug applications, biologics license applications and/or
emergency use authorization applications may be filed in any
jurisdictions for any potential indication for Pfizer’s product
candidates; whether and when any such applications that may be
pending or filed for any of Pfizer’s product candidates may be
approved by regulatory authorities, which will depend on myriad
factors, including making a determination as to whether the
product's benefits outweigh its known risks and determination of
the product's efficacy and, if approved, whether any such product
candidates will be commercially successful; decisions by regulatory
authorities impacting labeling, manufacturing processes, safety
and/or other matters that could affect the availability or
commercial potential of Pfizer’s products or product candidates,
including development of products or therapies by other companies;
manufacturing capabilities or capacity; uncertainties regarding the
impact of COVID-19 on Pfizer’s business, operations and financial
results; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023, and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008382241/en/
Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 10월(10) 2024
Pfizer (NYSE:PFE)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024
